Openbookopenbook
Equity
EXACT Sciences Corporation(EXAS)
USD --+0.00%
Reward52Moderate
Risk51Moderate
📊75%Data
Thin -6% profit margin · Revenue growing 23% YoY
EXAS
+0.0 · +0.00%
USD · NASDAQ
EXACT Sciences Corporation | Healthcare
Profitless Growth
Market Cap:19.75Bn
ℹ️
Reward Rating
52
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
51
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on EXAS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $105.81.

What is EXACT Sciences Corporation?

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.

EXAS · Verdict

Moderate reward · elevated risk

EXAS stands out on growth and cash flow, but watch the valuation signal.

Based on 88% data coverage

EXAS · Verdict

What’s working & what to watch

Strengths 2

  • Growth72/100

    Rev +15.9% CAGR · earnings -30.7%

  • Cash flow65/100

    11% free-cash-flow margin

Watchouts 4

  • Valuation12/100

    P/E 90.9× · PEG 1.38

  • Volatility35/100

    Below average

  • Balance sheet36/100

    Net debt/EBITDA 12.8×

  • Profitability44/100

    -6% net margin · -9% ROE

Model-based scoring. For information only — not financial advice.

What is EXACT Sciences Corporation?

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 19.75B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (52)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap19.75B
P/E RatioN/A
Dividend YieldN/A
52 Week High103.67
52 Week Low38.8118
Last AnnualDecember
IPO Date2/1/2001
IncorporatedUSA
Shares Outstanding191M
No. of Employees7,100
IndustryDiagnostics & Research
ExchangeNASDAQ
Beta1.422
CurrencyUSD
Websitewww.exactsciences.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.